Alpha 1-antichymotrypsin (ACT) is an alpha globulin glycoprotein which promotes respiratory health by inhibiting certain enzymes from attacking critical tissues, such as the lower respiratory tract. The ACT protein is produced in the liver, and is an acute phase protein that is induced during inflammation. Deficiency of this protein has been associated with liver disease. Mutations have been identified in patients with Parkinson disease and chronic obstructive pulmonary disease. Alpha 1-antichymotrypsin is also associated with the pathogenesis of Alzheimer’s disease as it enhances the formation of amyloid-fibrils in this disease.1
Principle of the Assay
The SDi Alpha 1-Antichymotrypsin (ACT) kit is a solid phase direct ELISA sandwich method. The standards, samples and controls are added into designated wells, coated with anti-ACT polyclonal antibody, along with the incubation buffer. After a simple washing step, an anti-ACT enzyme conjugate reagent is added into each well. After the excess enzyme conjugate is washed out, the substrate is added into each well. Upon the addition of the substrate, the intensity of color developed is directly proportional to the concentration of ACT in the samples. A standard curve is generated relating color intensity to the concentration of ACT.